KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Long-Term Deferred Tax (2016 - 2025)

Gsk (GSK) has 5 years of Long-Term Deferred Tax data on record, last reported at $7.5 billion in Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax changed N/A year-over-year to $7.5 billion; the TTM value through Dec 2023 reached $7.5 billion, changed N/A, while the annual FY2023 figure was $7.5 billion, N/A changed from the prior year.
  • Long-Term Deferred Tax reached $7.5 billion in Q4 2023 per GSK's latest filing, up from $7.0 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $7.5 billion in Q4 2023 and bottomed at $7.0 billion in Q4 2021.